Lilly (LLY) to Halt Enzastaurin Production Following Phase III; Sees Charge
Tweet
Share
E-mailGet Alerts LLY Hot Sheet
Price: $1,180.16 -2.25%
Financial Fact:
Other - net, expense (income): -27.2M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Other - net, expense (income): -27.2M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Eli Lilly and Company (NYSE: LLY) announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies.
Lilly plans to present data from this study at an upcoming scientific meeting.
Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30 million. The company's previously-issued financial guidance for 2013 remains unchanged.
Lilly plans to present data from this study at an upcoming scientific meeting.
Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30 million. The company's previously-issued financial guidance for 2013 remains unchanged.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fate Therapeutics starts Phase 2 lupus nephritis trial of FT819
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Mesoblast completes patient treatment in phase 3 back pain trial
Create E-mail Alert Related Categories
Corporate News, FDA, Guidance, Hot Corp. NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
